XML 70 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
Purchased Technology
12 Months Ended
Dec. 31, 2012
Purchased Technology [Abstract]  
Purchased Technology

6.    Purchased Technology

The carrying value of the purchased technology is comprised as follows:

 

                 
    December 31,  
    2012     2011  
    (In thousands)  

Gross carrying amount

  $     $ 4,533  

Less, accumulated amortization

          3,695  

Less, impairment

          598  
   

 

 

   

 

 

 

Net book value

  $     $  
   

 

 

   

 

 

 

Annual amortization of purchased technology was $0 for 2012 and $0.2 million for 2011 and 2010, respectively.

The purchased technology is comprised of patents for one of the Company’s carriers underlying unfractionated heparin (“UFH”) in a liquid form, UFH in a solid form and solid low molecular weight heparin. The patents expire June 30, 2014. In December 2011, the Company’s management reviewed the purchased technology in light of industry trends and advances in reformulating and stabilizing active pharmaceutical ingredients through the development of fractions and analogs, and determined that its technology is no longer applicable in the development of a potential future oral formulation of heparin. As such, the Company recognized an impairment of $0.6 million which represented the net book value at that time.